Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

164.66 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 113
Open 164.66
Bid (Size) 163.35 (1)
Ask (Size) 164.97 (1)
Prev. Close 164.66
Today's Range 164.66 - 164.66
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed. 
Via Benzinga
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision issues, difficulty breathing, and weakness. Ensure authenticity before... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+3.03%
+3.03%
1 Month
-8.35%
-8.35%
3 Month
+0.83%
+0.83%
6 Month
+13.15%
+13.15%
1 Year
+2.14%
+2.14%

More News

Read More
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
Powell And The Great Indecision
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
Via InvestorPlace
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Is AbbVie a Millionaire Maker?
Via The Motley Fool
Smart Money Is Betting Big In ABBV Options
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
What's Going On AbbVie Stock On Friday?
Via Benzinga
AbbVie Unusual Options Activity For April 05
Via Benzinga
Smart Money Is Betting Big In ABBV Options
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Via The Motley Fool
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
Via Benzinga
The 3 Best Stocks to Buy in April 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.